TG Therapeutics, Inc. (TGTX)
NASDAQ · Healthcare
TG Therapeutics, Inc. EBITDA 2016–2025
TG Therapeutics, Inc. annual/quarterly ebitda history and growth rate from 2021 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- TG Therapeutics, Inc. ebitda for the quarter ending March 31, 2026 was 34.8 M, a 303.56% increase year-over-year.
- TG Therapeutics, Inc. ebitda for the twelve months ending March 31, 2026 was -2.7 M.
- TG Therapeutics, Inc. annual ebitda for 2025 was 123.4 M, a 193.79% increase from 2024.
- TG Therapeutics, Inc. annual ebitda for 2024 was 42.0 M, a 101.48% increase from 2023.
- TG Therapeutics, Inc. annual ebitda for 2023 was 20.8 M, a 109.56% decrease from 2022.
- TG Therapeutics, Inc. annual ebitda for 2022 was -218.0 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
TG Therapeutics, Inc. EBITDA — FAQ
TG Therapeutics, Inc. (TGTX) ebitda over the last 10 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see TGTX's ebitda history?
The chart and table above show TG Therapeutics, Inc.'s ebitda by year and by quarter, including the growth rate.